



- Aboutorabi A. , Hadian, M., Ghaderi , H., Salehi , M., & Ghiasipour., M., (2015). Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer. *Global Journal of Health Science*; Vol. 7, No. 1; URL: <http://dx.doi.org/10.5539/gjhs.v7n1p98>
- Barbieri,V., Sanpaolo, P., Genovesi,i D. (2011). Interval Between Breast-Conserving Surgery and Start of Radiation Therapy in Early-Stage Breast Cancer is Not Predictive of Local Recurrence: A Single-Institution Experience. *Clinical Breast Cancer*, 11(2), 114-20.
- Bartsch, R., & Steger, G. G. (2011). Drugs for HER-2-positive Breast Cancer, 33–50. <http://doi.org/10.1007/978-3-0346-0094-1>
- Baselga, J., Perez, E. a, Pienkowski, T., & Bell, R. (2006). Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. *The Oncologist*, 11 Suppl 1(suppl 1), 4–12. <http://doi.org/10.1634/theoncologist.11-90001-4>
- Bines, J., & Eniu, A. (2008). Effective but cost-prohibitive drugs in breast cancer treatment: A clinician's perspective. *Cancer*, 113(8 SUPPL.), 2353–2358. <http://doi.org/10.1002/cncr.23837>
- Blamey, R. W. (2002). Guidelines on endocrine therapy of breast cancer EUSOMA. *European Journal of Cancer*, 38(5), 615–634.
- Breast Cancer 2011. *Annals of Oncology Advance Access* published June 27, 2011
- Bulutienė, G., Ostapenko,V., Vesėliunas, J. (2005). Influence of social factors on the quality of life after breast cancer surgical treatment. *Acta Medica Lituanica*. 12 (2),79-83
- Cervantes, A., Pentheroudakis, C. G., Board, E., Felip, E., Pavlidis, N., Stahel, R. A., ... Cherny, N. (2014). Eso-Esmo Consensus Guidelines Esmo Pocket Guidelines Provide You With A Concise Summary Of The Fundamental Recommendations Made In The Parent Guidelines In An Easily Accessible Format . This quick reference booklet provides you with the most important con, 2–55.
- Chilcott,J., Jones., M., and Wilkinson (2009). Docetaxel for the adjuvant treatment of early nodepositive breast cancer: a single technology appraisal. *Health Technology Assessment*; Vol. 13: Suppl. 1.
- Davari, M., Yazdanpanah, F., Aslani, A., Hosseini, M., Nazari, R., & Mokarian, F. (2013). The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan. *Int J Prev Med*. Jul; 4(7): 748–754.
- Dedes, K. J., Szucs, T. D., Imesch, P., Fedier, A., Fehr, M. K. & Fink, D. (2007) Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. *Annals of Oncology* 18: 1493–1499,



UNIVERSITAS  
GADJAH MADA

DISEASE FREE SURVIVAL, KUALITAS HIDUP DAN DIRECT MEDICAL COST PENDERITA KANKER  
PAYUDARA HER2  
POSITIF STADIUM AWAL YANG MENJALANI KEMOTERAPI ADJUVAN ANTI HER2 DI RSUP DR  
SARDJITO 2007-2014

WORO RUKMI PRATIWI, DR., M.KES., SP.PD, Prof. dr. Iwan Dwiprahasto, M.Med.Sc., PhD.; Dr. Erna Kristin, MSi.,  
Universitas Gadjah Mada, 2016 | Diunduh dari <http://etd.repository.ugm.ac.id/>  
Dokmanovic, M., & Wu, W. J. (2014). Trastuzumab-induced HER2 phosphorylation: exploring  
the mechanisms and implications. *Receptors & Clinical Investigation*, 1–5.  
<http://doi.org/10.14800/rci.340>

Eniu, A., Carlson, R. W., El Saghir, N. S., Bines, J., Bese, N. S., Vorobiof, D., ... Anderson, B. O. (2008). Guideline implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. *Cancer*, 113(8 SUPPL.), 2269–2281. <http://doi.org/10.1002/cncr.23843>

Gill, S., & Sargent, D. (2006). End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? *The Oncologist*, 11(6), 624–629. <http://doi.org/10.1634/theoncologist.11-6-624>

Gnant, M., Thomssen, C., Harbeck, N. (2015). St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion, *Breast Care*;10:124–130.

Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., ... Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. *The Lancet*, 382(9897), 1021–1028. [http://doi.org/10.1016/S0140-6736\(13\)61094-6](http://doi.org/10.1016/S0140-6736(13)61094-6)

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.J., & Panel members. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*: 1–18.

Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., Senn, H.J., & Panel members. (2011). Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early

Gonzalez-Angulo, a. M. (2006). Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer. *The Oncologist*, 11(8), 857–867. <http://doi.org/10.1634/theoncologist.11-8-857>

Howlader, N., Sean, F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014). Article US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status, (15), 1–8. <http://doi.org/10.1093/jnci/dju055>

Martin, M., Pienkowski, T., Mackey J., Pawlicki, M., Guastalla, J., Weaver, C., ... Vogel, C. (2005). Adjuvant Docetaxel for Node-Positive Breast Cancer. *www.nejm.org* june 2, 2005

Mikeljevic JS, Haward R, Johnston C, Crellin A, Dodwell D, Jones A, et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. *Br J Cancer*. 2004; 90: 1343-1348.

Murphy, C. G., & Morris, P. G. (2012). Recent advances in novel targeted therapies for HER2-positive breast cancer. *Anti-Cancer Drugs*, 23(8), 765–776. <http://doi.org/10.1097/CAD.0b013e328352d292>



UNIVERSITAS  
GADJAH MADA

**DISEASE FREE SURVIVAL, KUALITAS HIDUP DAN DIRECT MEDICAL COST PENDERITA KANKER  
PAYUDARA HER2  
POSITIF STADIUM AWAL YANG MENJALANI KEMOTERAPI ADJUVAN ANTI HER2 DI RSUP DR  
SARDJITO 2007-2014**

WORO RUKMI PRATIWI, DR., M.KES., SP.PD, Prof. dr. Iwan Dwiprahasto, M.Med.Sc., PhD.; Dr. Erna Kristin, MSi.,  
Universitas Gadjah Mada, 2016 | Diunduh dari <http://etd.repository.ugm.ac.id/>  
Nice. (2006). Trastuzumab for the adjuvant treatment of earlystage HER2-positive breast cancer.  
NICE Technology Appraisal Guidance TA107, (August).

Pandey, M., Thomas, B., Ramdas, K., & Ratheesan, K. (2006). Early Effect of Surgery on Quality of Life in Women with Operable Breast Cancer. *Jpn J Clin Oncol*; 36(7)468–472

Panduan Nasional Penanganan Kanker Payudara (PNPK) versi 1.0 2015, Komite Nasional Penanggulangan Kanker (KPKN) 2015, Kementerian Kesehatan.

Parise, C. a., & Caggiano, V. (2014). Breast cancer survival defined by the er/pr/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. *Journal of Cancer Epidemiology*, 2014. <http://doi.org/10.1155/2014/469251>

Punglia RS, Saito AM, Neville BA, Earle CC, Weeks JC. (2010) Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. *BMJ*..

Romond, E. H., Perez, E. a, Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., ... Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *The New England Journal of Medicine*, 353(16), 1673–1684. <http://doi.org/10.1056/NEJMoa052122>

Stenzinger, A., von Winterfeld, M., Aulmann, S., Warth, A., Weichert, W., Denkert, C., ... Klauschen, F. (2012). Quantitative Analysis of Diagnostic Guidelines for HER2-Status Assessment. *The Journal of Molecular Diagnostics*, 14(3), 199–205. <http://doi.org/10.1016/j.jmoldx.2012.01.012>

Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. a., Lichtensztajn, D., ... Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. *Breast Cancer Research and Treatment*, 127(2), 471–478. <http://doi.org/10.1007/s10549-010-1173-8>

Theriault, R. L., Carlson, R. W., Allred, C., Anderson, B. O., Burstein, H. J., Edge, S. B., ... Zellars, R. (2013). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, 1–174. Retrieved from [http://infoonco.es/wp-content/uploads/2011/10/breast\\_cancer\\_2.2013.pdf](http://infoonco.es/wp-content/uploads/2011/10/breast_cancer_2.2013.pdf)

Wilkinson, N., Shahryarnejad, A., Winston, J.A., Watroba, N., Edge, S.B., (2003). Concordance with Breast Cancer Pathology Reporting Practice Guidelines. *J Am Coll. Surg*;196:38-43.

Williams F (2015) Assessment of Breast Cancer Treatment Delay Impact on Prognosis and Survival: a Look at the Evidence from Systematic Analysis of the Literature. A Pilot Study. *J Cancer Biol Res* 3(4): 1071.

Zhang, X., Zhang, X.-J., Zhang, T.-Y., Yu, F.-F., Wei, X., Li, Y.-S., & He, J. (2014). Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review. *BMC Cancer*, 14(1), 625. <http://doi.org/10.1186/1471-2407-14-625>